Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

Müller, Svenja; Maintz, Laura; Bieber, Thomas

doi:10.1111/all.16009

Cited by 30 publications

(1 citation statement)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of type-2 inflammation in AD, and especially that of IL-4/IL-13, is exemplified by the efficacy of therapies targeting these cytokines, e.g. the anti-IL-4Ra antibody dupilumab and the anti-IL-13 antibodies tralokinumab and lebrikizumab for moderate to severe AD (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30). However, the pathophysiology of AD is more complex with heterogenous phenotypes underlying different endotypes, with the involvement of type-1 (e.g.…”

Section: Introductionmentioning

confidence: 99%

Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?

Migayron,

Bordes,

Closs

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Chronic inflammatory skin diseases are multifactorial diseases that combine genetic predisposition, environmental triggers, and metabolic disturbances associated with abnormal immune responses. From an immunological perspective, the better understanding of their physiopathology has demonstrated a large complex network of immune cell subsets and related cytokines that interact with both epidermal and dermal cells. For example, in type-1-associated diseases such as alopecia areata, vitiligo, and localized scleroderma, recent evidence suggests the presence of a type-2 inflammation that is well known in atopic dermatitis. Whether this type-2 immune response has a protective or detrimental impact on the development and chronicity of these diseases remains to be fully elucidated, highlighting the need to better understand its involvement for the management of patients. This mini-review explores recent insights regarding the potential role of type-2-related immunity in alopecia areata, vitiligo, and localized scleroderma.

show abstract

Section: Introductionmentioning

confidence: 99%

Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?

Migayron,

Bordes,

Closs

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Atopic dermatitis: pathogenesis and therapeutic intervention

Yue,

Zhou,

Wang

et al. 2024

MedComm

View full text Add to dashboard Cite

The skin serves as the first protective barrier for nonspecific immunity and encompasses a vast network of skin‐associated immune cells. Atopic dermatitis (AD) is a prevalent inflammatory skin disease that affects individuals of all ages and races, with a complex pathogenesis intricately linked to genetic, environmental factors, skin barrier dysfunction as well as immune dysfunction. Individuals diagnosed with AD frequently exhibit genetic predispositions, characterized by mutations that impact the structural integrity of the skin barrier. This barrier dysfunction leads to the release of alarmins, activating the type 2 immune pathway and recruiting various immune cells to the skin, where they coordinate cutaneous immune responses. In this review, we summarize experimental models of AD and provide an overview of its pathogenesis and the therapeutic interventions. We focus on elucidating the intricate interplay between the immune system of the skin and the complex regulatory mechanisms, as well as commonly used treatments for AD, aiming to systematically understand the cellular and molecular crosstalk in AD‐affected skin. Our overarching objective is to provide novel insights and inform potential clinical interventions to reduce the incidence and impact of AD.

show abstract